| Colleen Molloy Rickey, MD | |
|
8800 N Tryon St, Charlotte, NC 28262-3300 | |
| (704) 863-6241 | |
| Not Available |
| Full Name | Colleen Molloy Rickey |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 22 Years |
| Location | 8800 N Tryon St, Charlotte, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225100134 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 2005-00979 (North Carolina) | Secondary |
| 207R00000X | Internal Medicine | 2005-00979 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carolinas Medical Center/behav Health | Charlotte, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carolinas Physicians Network Inc | 3375449655 | 1613 |
News Archive
Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has signed a development agreement with Biosara Corporation, a medical device company targeting wound dressings for major medical and healthcare providers, along with the multi-billion dollar organized sports athlete markets.
Even lawmakers most loyal to their leaders and political party on occasion buck them with a flash of independence or bipartisanship. That includes some of the six Republicans and six Democrats given the task of finding up to another $1.5 trillion deficit savings over the next decade.
A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.
Researchers from VU University Medical Center in Amsterdam have reported that RapidArc® radiotherapy from Varian Medical Systems has clinical advantages over earlier fixed-beam approaches to stereotactic treatments of lung tumors. Their findings, based on treatment of 85 medically inoperable lung cancer patients, were reported at the recent annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago and a condensed version has been published in the 'Green Journal' (Radiotherapy and Oncology) 93 (2009).
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD).
› Verified 7 days ago
| Entity Name | Carolinas Physicians Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477878890 PECOS PAC ID: 3375449655 Enrollment ID: O20031219000455 |
News Archive
Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has signed a development agreement with Biosara Corporation, a medical device company targeting wound dressings for major medical and healthcare providers, along with the multi-billion dollar organized sports athlete markets.
Even lawmakers most loyal to their leaders and political party on occasion buck them with a flash of independence or bipartisanship. That includes some of the six Republicans and six Democrats given the task of finding up to another $1.5 trillion deficit savings over the next decade.
A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.
Researchers from VU University Medical Center in Amsterdam have reported that RapidArc® radiotherapy from Varian Medical Systems has clinical advantages over earlier fixed-beam approaches to stereotactic treatments of lung tumors. Their findings, based on treatment of 85 medically inoperable lung cancer patients, were reported at the recent annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago and a condensed version has been published in the 'Green Journal' (Radiotherapy and Oncology) 93 (2009).
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Colleen Molloy Rickey, MD Po Box 19305, Charlotte, NC 28219-9305 Ph: () - | Colleen Molloy Rickey, MD 8800 N Tryon St, Charlotte, NC 28262-3300 Ph: (704) 863-6241 |
News Archive
Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has signed a development agreement with Biosara Corporation, a medical device company targeting wound dressings for major medical and healthcare providers, along with the multi-billion dollar organized sports athlete markets.
Even lawmakers most loyal to their leaders and political party on occasion buck them with a flash of independence or bipartisanship. That includes some of the six Republicans and six Democrats given the task of finding up to another $1.5 trillion deficit savings over the next decade.
A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.
Researchers from VU University Medical Center in Amsterdam have reported that RapidArc® radiotherapy from Varian Medical Systems has clinical advantages over earlier fixed-beam approaches to stereotactic treatments of lung tumors. Their findings, based on treatment of 85 medically inoperable lung cancer patients, were reported at the recent annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago and a condensed version has been published in the 'Green Journal' (Radiotherapy and Oncology) 93 (2009).
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD).
› Verified 7 days ago
Dr. Anish Kaushik Vani, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 125 Queens Rd Ste 200, Charlotte, NC 28204 Phone: 704-343-9800 Fax: 704-347-2011 | |
John Michael Fedor, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1237 Harding Pl, Ste 3100, Charlotte, NC 28204 Phone: 704-373-0212 | |
Dr. Michael Warren Smith, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6115 Park South Dr Ste 100, Charlotte, NC 28210 Phone: 704-554-8787 Fax: 704-554-8774 | |
William Lane Jr., MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-4490 | |
Dr. Alagusivakumari Rameshbabu, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10648 Park Rd, Charlotte, NC 28210 Phone: 704-667-8050 | |
Shibin Thomas Jacob, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 E W T Harris Blvd, Bldg 5000 Suite #5101, Charlotte, NC 28262 Phone: 704-863-5847 | |
Oscar Sven Brann, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6060 Piedmont Row Dr S Fl 10, Charlotte, NC 28287 Phone: 704-489-3094 |